Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay

Weidong Huang, Monica Reinholz, Jodi Weidler, Yolanda Lie, Agnes Paquet, Jeannette Whitcomb, Wilma Lingle, Robert Brian Jenkins, Beiyun Chen, Jeffrey S. Larson, Yuping Tan, Thomas Sherwood, Michael Bates, Edith A. Perez

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The accuracy and reliability of immunohistochemical analysis and in situ hybridization for the assessment of HER2 status remains a subject of debate. We developed a novel assay (HERmark Breast Cancer Assay, Monogram Biosciences, South San Francisco, CA) that provides precise quantification of total HER2 protein expression (H2T) and HER2 homodimers (H2D) in formalin-fixed, paraffin-embedded tissue specimens. H2T and H2D results of 237 breast cancers were compared with those of immunohistochemical studies and fluorescence in situ hybridization (FISH) centrally performed at the Mayo Clinic, Rochester, MN. H2T described a continuum across a wide dynamic range (∼2.5 log). Excluding the equivocal cases, HERmark showed 98% concordance with immunohistochemical studies for positive and negative assay values. For the 94 immunohistochemically equivocal cases, 67% and 39% concordance values were observed between HERmark and FISH for positive and negative assay values, respectively. Polysomy 17 in the absence of HER2 gene amplification did not result in HER2 overexpression as evaluated quantitatively using the HERmark assay.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume134
Issue number2
DOIs
StatePublished - Aug 2010

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
erbB-2 Genes
San Francisco
Gene Amplification
Paraffin
Formaldehyde
In Situ Hybridization
Proteins

Keywords

  • Breast cancer
  • Central HER2 testing
  • Concordance
  • HER2 homodimers
  • Polysomy 17
  • Quantitative total HER2 expression

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. / Huang, Weidong; Reinholz, Monica; Weidler, Jodi; Lie, Yolanda; Paquet, Agnes; Whitcomb, Jeannette; Lingle, Wilma; Jenkins, Robert Brian; Chen, Beiyun; Larson, Jeffrey S.; Tan, Yuping; Sherwood, Thomas; Bates, Michael; Perez, Edith A.

In: American Journal of Clinical Pathology, Vol. 134, No. 2, 08.2010, p. 303-311.

Research output: Contribution to journalArticle

Huang, W, Reinholz, M, Weidler, J, Lie, Y, Paquet, A, Whitcomb, J, Lingle, W, Jenkins, RB, Chen, B, Larson, JS, Tan, Y, Sherwood, T, Bates, M & Perez, EA 2010, 'Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay', American Journal of Clinical Pathology, vol. 134, no. 2, pp. 303-311. https://doi.org/10.1309/AJCP3BZY4YAFNTRG
Huang, Weidong ; Reinholz, Monica ; Weidler, Jodi ; Lie, Yolanda ; Paquet, Agnes ; Whitcomb, Jeannette ; Lingle, Wilma ; Jenkins, Robert Brian ; Chen, Beiyun ; Larson, Jeffrey S. ; Tan, Yuping ; Sherwood, Thomas ; Bates, Michael ; Perez, Edith A. / Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. In: American Journal of Clinical Pathology. 2010 ; Vol. 134, No. 2. pp. 303-311.
@article{2f7e5c382dc14813b91ce5cb11247537,
title = "Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay",
abstract = "The accuracy and reliability of immunohistochemical analysis and in situ hybridization for the assessment of HER2 status remains a subject of debate. We developed a novel assay (HERmark Breast Cancer Assay, Monogram Biosciences, South San Francisco, CA) that provides precise quantification of total HER2 protein expression (H2T) and HER2 homodimers (H2D) in formalin-fixed, paraffin-embedded tissue specimens. H2T and H2D results of 237 breast cancers were compared with those of immunohistochemical studies and fluorescence in situ hybridization (FISH) centrally performed at the Mayo Clinic, Rochester, MN. H2T described a continuum across a wide dynamic range (∼2.5 log). Excluding the equivocal cases, HERmark showed 98{\%} concordance with immunohistochemical studies for positive and negative assay values. For the 94 immunohistochemically equivocal cases, 67{\%} and 39{\%} concordance values were observed between HERmark and FISH for positive and negative assay values, respectively. Polysomy 17 in the absence of HER2 gene amplification did not result in HER2 overexpression as evaluated quantitatively using the HERmark assay.",
keywords = "Breast cancer, Central HER2 testing, Concordance, HER2 homodimers, Polysomy 17, Quantitative total HER2 expression",
author = "Weidong Huang and Monica Reinholz and Jodi Weidler and Yolanda Lie and Agnes Paquet and Jeannette Whitcomb and Wilma Lingle and Jenkins, {Robert Brian} and Beiyun Chen and Larson, {Jeffrey S.} and Yuping Tan and Thomas Sherwood and Michael Bates and Perez, {Edith A.}",
year = "2010",
month = "8",
doi = "10.1309/AJCP3BZY4YAFNTRG",
language = "English (US)",
volume = "134",
pages = "303--311",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay

AU - Huang, Weidong

AU - Reinholz, Monica

AU - Weidler, Jodi

AU - Lie, Yolanda

AU - Paquet, Agnes

AU - Whitcomb, Jeannette

AU - Lingle, Wilma

AU - Jenkins, Robert Brian

AU - Chen, Beiyun

AU - Larson, Jeffrey S.

AU - Tan, Yuping

AU - Sherwood, Thomas

AU - Bates, Michael

AU - Perez, Edith A.

PY - 2010/8

Y1 - 2010/8

N2 - The accuracy and reliability of immunohistochemical analysis and in situ hybridization for the assessment of HER2 status remains a subject of debate. We developed a novel assay (HERmark Breast Cancer Assay, Monogram Biosciences, South San Francisco, CA) that provides precise quantification of total HER2 protein expression (H2T) and HER2 homodimers (H2D) in formalin-fixed, paraffin-embedded tissue specimens. H2T and H2D results of 237 breast cancers were compared with those of immunohistochemical studies and fluorescence in situ hybridization (FISH) centrally performed at the Mayo Clinic, Rochester, MN. H2T described a continuum across a wide dynamic range (∼2.5 log). Excluding the equivocal cases, HERmark showed 98% concordance with immunohistochemical studies for positive and negative assay values. For the 94 immunohistochemically equivocal cases, 67% and 39% concordance values were observed between HERmark and FISH for positive and negative assay values, respectively. Polysomy 17 in the absence of HER2 gene amplification did not result in HER2 overexpression as evaluated quantitatively using the HERmark assay.

AB - The accuracy and reliability of immunohistochemical analysis and in situ hybridization for the assessment of HER2 status remains a subject of debate. We developed a novel assay (HERmark Breast Cancer Assay, Monogram Biosciences, South San Francisco, CA) that provides precise quantification of total HER2 protein expression (H2T) and HER2 homodimers (H2D) in formalin-fixed, paraffin-embedded tissue specimens. H2T and H2D results of 237 breast cancers were compared with those of immunohistochemical studies and fluorescence in situ hybridization (FISH) centrally performed at the Mayo Clinic, Rochester, MN. H2T described a continuum across a wide dynamic range (∼2.5 log). Excluding the equivocal cases, HERmark showed 98% concordance with immunohistochemical studies for positive and negative assay values. For the 94 immunohistochemically equivocal cases, 67% and 39% concordance values were observed between HERmark and FISH for positive and negative assay values, respectively. Polysomy 17 in the absence of HER2 gene amplification did not result in HER2 overexpression as evaluated quantitatively using the HERmark assay.

KW - Breast cancer

KW - Central HER2 testing

KW - Concordance

KW - HER2 homodimers

KW - Polysomy 17

KW - Quantitative total HER2 expression

UR - http://www.scopus.com/inward/record.url?scp=77955597966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955597966&partnerID=8YFLogxK

U2 - 10.1309/AJCP3BZY4YAFNTRG

DO - 10.1309/AJCP3BZY4YAFNTRG

M3 - Article

C2 - 20660336

AN - SCOPUS:77955597966

VL - 134

SP - 303

EP - 311

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -